MeiraGTx Holdings plc - Ordinary Shares (MGTX): Price and Financial Metrics

MeiraGTx Holdings plc - Ordinary Shares (MGTX): $6.41

0.24 (+3.89%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add MGTX to Watchlist
Sign Up

MGTX Price/Volume Stats

Current price $6.41 52-week high $8.35
Prev. close $6.17 52-week low $3.49
Day low $6.12 Volume 144,100
Day high $6.49 Avg. volume 156,169
50-day MA $6.37 Dividend yield N/A
200-day MA $5.96 Market Cap 407.66M

MGTX Stock Price Chart Interactive Chart >


MeiraGTx Holdings plc - Ordinary Shares (MGTX) Company Bio


MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom.


MGTX Latest News Stream


Event/Time News Detail
Loading, please wait...

MGTX Latest Social Stream


Loading social stream, please wait...

View Full MGTX Social Stream

Latest MGTX News From Around the Web

Below are the latest news stories about MEIRAGTX HOLDINGS PLC that investors may wish to consider to help them evaluate MGTX as an investment opportunity.

Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 221.8% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 25, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!

William White on InvestorPlace | December 21, 2023

J&J bets bigger on MeiraGTx’s eye gene therapy

Ahead of a Phase 3 readout that could come next year, the pharma is paying $130 million in upfront and near-term cash for rights to the retinitis pigmentosa treatment that it didn’t already own.

Yahoo | December 21, 2023

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

- MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) for a total of up to $415 million - MeiraGTx to receive $130 million in upfront and near-term milestone payments as part of the agreement - MeiraGTx to receive up to an additional $285 million upon first commercial sales of bota-vec in U.S. and EU and manufacturing technology transfer LONDON and NEW YORK, Dec. 21, 2023 (G

Yahoo | December 21, 2023

The past three years for MeiraGTx Holdings (NASDAQ:MGTX) investors has not been profitable

The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the last three...

Yahoo | December 14, 2023

Read More 'MGTX' Stories Here

MGTX Price Returns

1-mo 8.46%
3-mo 22.80%
6-mo 6.21%
1-year -21.16%
3-year -53.88%
5-year -64.72%
YTD -8.69%
2023 7.67%
2022 -72.54%
2021 56.80%
2020 -24.38%
2019 107.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!